Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth prospects during the specified Class Period from December 12, 2024, to June 30, 2025 [1][4]. Company Overview - Centene Corporation is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Allegations and Misleading Information - The lawsuit claims that Centene's management misled investors by presenting a false impression of reliable information concerning the company's projected revenue and growth, emphasizing strong enrollment rates and low morbidity levels [4]. - Contrary to these claims, the complaint alleges that there were adverse enrollment trends and worsening morbidity rates that were concealed from investors [5]. Financial Impact and Guidance Revision - On July 1, 2025, Centene withdrew its 2025 guidance, revealing disappointing findings from an internal analysis that indicated market growth across 22 states, which account for approximately 72% of its marketplace membership, was significantly below expectations [6]. - Following this announcement, Centene revised its earnings guidance downward to approximately $1.8 billion, translating to an adjusted diluted EPS of $2.75 [6]. - The stock price of Centene dropped by more than 40% after the guidance revision, resulting in substantial financial harm to investors [7].
Centene Corporation Investors: Please contact the Portnoy Law Firm to recover your losses; September 8, 2025 Deadline to file Lead Plaintiff Motion